Line 109: |
Line 109: |
| PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549 | | PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549 |
| |- | | |- |
| + | | |
| + | |Classic ependymoma (no WHO grade assigned) |
| + | |'''Gain:''' 1q, 5, 7, 9, 11, 18, 20<br> |
| + | '''Loss:''' 1p, 3, -6/6q, 9p, 13q, 17, 22 |
| + | |Usually intracranial, spinal tumors (myxopapillary) are rare; 80% of pediatric tumors develop in posterior fossa (PF); Supratentorial tumors preferentially show monosomy 9; 1q gain is unfavorable prognostic indicator in PF tumors; spinal tumors associated with NF2 (germline); children have worse outcomes than adults |
| + | |PMID:25965575; PMID:22338015; PMID:28371821 |
| + | |- |
| + | | |
| + | |Subependymoma, WHO grade I |
| + | |Typically '''balanced genomes'''<br> |
| + | '''Loss:''' -6/6q in spinal tumors |
| + | |No diagnostic mutations |
| + | |Favorable prognosis |
| + | |WHO CNS Tumors (2016) <br> |
| + | PMID:21959044; PMID:21840481<br> |
| + | |- |
| + | | |
| + | |Myxopapillary ependymoma, WHO grade I |
| + | |'''Aneuploidy:''' multiple chromosomes lost and gained |
| + | |'''Mutation:''' NF2 (including germline) in spinal tumors |
| + | |Less common but more aggressive in children |
| + | |PMID:25965575; PMCID:3991130; PMID:20425037; PMID:25957288; PMID:25965575; PMID:22516549 |
| + | |- |
| + | | |
| + | | |